Sensus Healthcare Q2 2026: Revenue Plunges 68.5%, $5.7M Tax Valuation Allowance Deepens Loss

summarizeSummary

Sensus Healthcare reported Q2 2026 revenue of $2.29 million, down 68.5% year-over-year, and a net loss of $8.75 million, including a $5.7 million tax valuation allowance. The company's cash reserves of $15.2 million are expected to fund operations for the next 12 months.

check_boxKey Events · Earnings and Guidance · SRTS

• Revenue Plunges 68.5%

  Q2 2026 revenue was $2.29 million, down from $7.32 million in Q2 2025, driven by a drop in units sold from 19 to 6 and no sales to a historically large customer.

• Net Loss Widens to $8.75M

  Net loss for Q2 2026 was $8.75 million, compared to $1.04 million in Q2 2025, primarily due to a $5.7 million valuation allowance against deferred tax assets.

• Cash Runway Adequate

  Cash, restricted cash, and equivalents totaled $15.2 million at June 30, 2026, which management believes is sufficient to fund operations for the next 12 months.

• New Credit Facility Limited

  The CNB Credit Facility provides up to $15 million, but only $2 million is available initially, with $13 million restricted and $2.2 million held as collateral.

auto_awesomeAnalysis · SRTS · Industrial Applications And Services

Sensus Healthcare's Q2 2026 results confirm a severe revenue decline and a much larger net loss than the prior year, driven by a $5.7 million valuation allowance against deferred tax assets. The company's cash position remains adequate for the next 12 months, but the loss of a historically large customer and a shift to lower-margin international sales and Fair Deal Agreements are pressuring profitability. The new CNB credit facility provides limited near-term liquidity, with only $2 million available initially and $13 million restricted.